

PRESS RELEASE

1 JUNE 2026

NANOLOGICA'S CFO LEAVES THE COMPANY

Nanologica's Chief Financial Officer Eva Osterman has decided to leave the company. Eva will remain in the Group until 31 August 2026 to ensure a smooth handover and support the recruitment of her successor. The recruitment process has begun.

"Since she started in 2017, Eva has had a central role in the company and been a big part of shaping the Nanologica we are today," says Andreas Bhagwani, CEO of Nanologica AB. "As CFO, she has been crucial for several important milestones, including the listing on Nasdaq Stockholm in 2022, and she has created the conditions for being able to handle the requirements that exist for a listed company even as a small company. Eva's broad knowledge and proven capacity has been a great asset to the company and I would like to extend a big and warm thank you for her support and great commitment over the years and wish her all the best in the future."

"After more than 9 years in the company, it is time for me to move on. The company and the team have meant a lot to me and I feel proud of the journey we have made together. I am convinced that the company is strong today and is well equipped for continued growth. I will follow future developments with great interest," says Eva Osterman.

Eva will continue in her role as CFO until August 31st to ensure a smooth handover and support the recruitment a new CFO. The work of finding her successor has begun.

For further information, please contact:

Johanna Westerberg, Director IR, Communications and Marketing

Ph: +46 72 211 21 90 or e-mail: ir@nanologica.com

About Nanologica AB (publ)

Nanologica is a Swedish life science group that offers advanced solutions in the development, manufacture and purification of pharmaceutical substances. By combining expertise in materials science, nanotechnology, and chemical process development, with services in contract development and manufacturing, Nanologica provides an integrated platform that supports the entire value chain from early development to commercial production of pharmaceutical substances. Nanologica's offering enables efficient and scalable production of drug substances, with particular strength within complex molecules and peptide-based drugs, such as treatments for diabetes and obesity. The company positions itself as a long-term partner to the pharmaceutical industry, with the goal of enabling more patients around the world to have access to life-saving treatments and cost-effective medicines. The Group has about 70 employees and is headquartered in Södertälje. Nanologica's share (ticker NICA) has been listed on Nasdaq Stockholm's main market since 2022. For further information, please visit www.nanologica.com.